PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR)BSA Free [NB300-537]

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) [NB300-537] - 293T cell lysate. Image from verified customer review.

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537]

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) [NB300-537] - Analysis of PPAR alpha in Jurkat cells compared to an isotype control (blue).

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537]

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) [NB300-537] - Analysis of PPAR alpha in Hela cells compared to an isotype control (blue).

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537]

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) [NB300-537] - Analysis of PPAR alpha in 3T3 cells compared to an isotype control (blue).

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537]

Flow Cytometry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) [NB300-537] - An intracellular stain was performed on Jurkat cells with PPAR alpha/NR1C1 Antibody (3B6/PPAR) NB300-537AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537]

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] - PPAR alpha/NR1C1 was knocked down with siRNA in primary cultured rat cardiomyocytes. Image from verified customer review.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

The metabolic remodeling process in natural kidney aging. A Representative images of Oil Red O staining in the 24-month-old and 6-month-old group (n = 6), scale bar = 50 μm; B, C the downregulated protein levels of FAO markers (i.e., PPAR alpha, ACOX1, and CPT1A) and upregulated protein levels of glycolysis markers (i.e., HK2 and PDK1) by western blot, and their semi-quantitative analyses (n = 6); D immunostaining for GLIS1 (red) and PPAR alpha (green), with DAPI (blue) counterstaining by IF staining in the 24-month-old and 6-month-old group (n = 6), scale bar = 50 μm; E lactate levels in the 24-month-old and 6-month-old group (n = 6); F the downregulated protein levels of PPAR alpha, ACOX1, and CPT1A, and up-regulated protein levels of HK2 and PDK1 in the 24-month-old group by IHC assay and their semi-quantitative analyses (n = 6), scale bar = 50 μm. The data are expressed as the mean +/- SD of three independent experiments. **P < .01 or ***P < .001 versus the 6-month-old group by Student’s t-test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39736678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

Bioinformatics analysis of proteomic results.(A). Hierarchical clustering analysis of the differentially expressed proteins in the two groups (si-CD151 vs si-NC) (n = 3) (B) The differentially expressed proteins analyzed by volcano plots between every two groups (si-CD151 vs si-NC) (C) Circus plots of GO Classification Annotation of differential protein. (D) KEGG pathways of differentially expressed proteins. OS: Organismal Systems; M: Metabolism; GIP: Genetic Information Processing; CP: Cellular Processes. (E) Western blot analysis of PPAR-alpha, PCG-1 alpha and GAPDH) in CMs under PE, quantified by Image J (n = 4). (F) Western blot analysis of PPAR-gamma and GAPDH) in CFs under Ang-II, quantified by Image J (n = 4). Data are expressed as mean +/- SEM. Image collected and cropped by CiteAb from the following open publication (https://dx.plos.org/10.1371/journal.pone.0297121), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

The over-expressed GLIS1 suppressed metabolic remodeling from FAO to glycolysis in the accelerated aging mouse model. A The representative images of mouse kidney tissue in the control, AAV-Vector and AAV-GLIS1 group stained with Oil Red O (n = 6), scale bar = 50 μm; B, C downregulated protein levels of PPAR alpha, ACOX1, and CPT1A in the accelerated aging mouse model were reversed in the presence of AAV-GLIS1, while upregulated protein levels of HK2 and PKD1 in the accelerated aging mouse model were reduced by introducing AAV-GLIS1 (n = 6); D lactate levels in the control, AAV-Vector and AAV-GLIS1 group (n = 6); E the reversed effect of PPAR alpha, ACOX1 and CPT1A levels, as well as HK2 and PDK1 levels in the presence of AAV-GLIS1 by IHC assay, and their semi-quantitative analyses (n = 6), scale bar = 50 μm; F immunostaining for PPAR alpha, ACOX1, CPTA1, HK2, and PDK1 (green), with DAPI (blue) counterstaining by IF staining in accelerated aging mouse model (n = 6), scale bar = 50 μm. The data are expressed as the mean +/- SD of three independent experiments. **P < .01 or ***P < .001 versus the AAV-vector group by one-way ANOVA Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39736678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

The ablation of METTL3 triggered metabolic remodeling and aggravated cell senescence renal fibrosis. A Protein levels of GLIS1, PPAR alpha, ACOX1, CPT1A, HK2, PDK1, FN, alpha-SMA, and P16INK4A by western blot in the vector and siMETTL3 group, and their semi-quantitative analyses (n = 3); B representative images of Oil Red O staining in the vector and siMETTL3 group (n = 3), scale bar = 50 μm; C double immunostaining for GLS1 and PPAR alpha, ACOX1, CPT1A, HK2, PDK1, and alpha-SMA by IF staining (n = 3) scale bar = 50 μm. The data are expressed as the mean +/- SD of three independent experiments. **P < .01 or ***P < .001 versus the vector group by Student’s t-test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39736678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

CCM treatment upregulates AMPK and PPAR-alpha pathways. (a) Western blot analysis of the expression of AMPK. Densitometric analysis is shown in the bar graph. (b) Western blot analysis of the expressions of PPAR-alpha and PGC-1 alpha. Densitometric analysis is shown in the bar graph. Data are expressed as mean values +/- SD (*P < 0.05 compared with the sham group; #P < 0.05 compared with HF group). Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/35799598), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

The metabolic remodeling process in natural kidney aging. A Representative images of Oil Red O staining in the 24-month-old and 6-month-old group (n = 6), scale bar = 50 μm; B, C the downregulated protein levels of FAO markers (i.e., PPAR alpha, ACOX1, and CPT1A) and upregulated protein levels of glycolysis markers (i.e., HK2 and PDK1) by western blot, and their semi-quantitative analyses (n = 6); D immunostaining for GLIS1 (red) and PPAR alpha (green), with DAPI (blue) counterstaining by IF staining in the 24-month-old and 6-month-old group (n = 6), scale bar = 50 μm; E lactate levels in the 24-month-old and 6-month-old group (n = 6); F the downregulated protein levels of PPAR alpha, ACOX1, and CPT1A, and up-regulated protein levels of HK2 and PDK1 in the 24-month-old group by IHC assay and their semi-quantitative analyses (n = 6), scale bar = 50 μm. The data are expressed as the mean +/- SD of three independent experiments. **P < .01 or ***P < .001 versus the 6-month-old group by Student’s t-test Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39736678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunohistochemistry: PPAR alpha/NR1C1 Antibody (3B6/PPAR) - BSA Free [NB300-537] -

The over-expressed GLIS1 suppressed metabolic remodeling from FAO to glycolysis in the accelerated aging mouse model. A The representative images of mouse kidney tissue in the control, AAV-Vector and AAV-GLIS1 group stained with Oil Red O (n = 6), scale bar = 50 μm; B, C downregulated protein levels of PPAR alpha, ACOX1, and CPT1A in the accelerated aging mouse model were reversed in the presence of AAV-GLIS1, while upregulated protein levels of HK2 and PKD1 in the accelerated aging mouse model were reduced by introducing AAV-GLIS1 (n = 6); D lactate levels in the control, AAV-Vector and AAV-GLIS1 group (n = 6); E the reversed effect of PPAR alpha, ACOX1 and CPT1A levels, as well as HK2 and PDK1 levels in the presence of AAV-GLIS1 by IHC assay, and their semi-quantitative analyses (n = 6), scale bar = 50 μm; F immunostaining for PPAR alpha, ACOX1, CPTA1, HK2, and PDK1 (green), with DAPI (blue) counterstaining by IF staining in accelerated aging mouse model (n = 6), scale bar = 50 μm. The data are expressed as the mean +/- SD of three independent experiments. **P < .01 or ***P < .001 versus the AAV-vector group by one-way ANOVA Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/39736678), licensed under a CC-BY license. Not internally tested by Novus Biologicals.